Sutent 25 mg hard capsules clinical trials

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

This study looks at a new combination of two drugs, pembrolizumab and epacadostat, for advanced kidney cancer. It compares this combination to standard treatments (sunitinib or pazopanib) to see if it works better and is safe for adults.